Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer

Since the discovery of targeted therapy with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have been introduced as the first-line treatment for non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations. Co...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Li, Wang, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709813/
https://www.ncbi.nlm.nih.gov/pubmed/33200229
http://dx.doi.org/10.3892/or.2020.7851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709813/
https://www.ncbi.nlm.nih.gov/pubmed/33200229
http://dx.doi.org/10.3892/or.2020.7851

Ejemplares similares